Braver Wealth Management Lowers stake in AbbVie Inc (ABBV)

AbbVie Inc (ABBV) : Braver Wealth Management reduced its stake in AbbVie Inc by 1.44% during the most recent quarter end. The investment management company now holds a total of 122,706 shares of AbbVie Inc which is valued at $7,947,668 after selling 1,794 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Jul 13, 2016.AbbVie Inc makes up approximately 1.33% of Braver Wealth Management’s portfolio.

Other Hedge Funds, Including , Culbertson A N Co Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 2,460 additional shares and now holds a total of 84,977 shares of AbbVie Inc which is valued at $5,503,960. AbbVie Inc makes up approx 1.98% of Culbertson A N Co Inc’s portfolio.Quotient Investors boosted its stake in ABBV in the latest quarter, The investment management firm added 7,280 additional shares and now holds a total of 12,900 shares of AbbVie Inc which is valued at $835,533. AbbVie Inc makes up approx 0.38% of Quotient Investors’s portfolio.Curbstone Financial Management Corp reduced its stake in ABBV by selling 1,100 shares or 5.3% in the most recent quarter. The Hedge Fund company now holds 19,672 shares of ABBV which is valued at $1,262,156. AbbVie Inc makes up approx 0.42% of Curbstone Financial Management Corp’s portfolio. First American Trust Fsb added ABBV to its portfolio by purchasing 3,360 company shares during the most recent quarter which is valued at $215,578. AbbVie Inc makes up approx 0.08% of First American Trust Fsb’s portfolio.

AbbVie Inc opened for trading at $63.23 and hit $63.77 on the upside on Monday, eventually ending the session at $63.56, with a gain of 0.38% or 0.24 points. The heightened volatility saw the trading volume jump to 63,84,755 shares. Company has a market cap of $102,799 M.

On the company’s financial health, AbbVie Inc reported $1.15 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.14. The company had revenue of $5958.00 million for the quarter, compared to analysts expectations of $5978.41 million. The company’s revenue was up 18.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.94 EPS.

Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.

AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.

Leave a Reply

AbbVie Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on AbbVie Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.